Latest News

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.

Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.

Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.

Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.

At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.

A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.

A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.

Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.

HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.

These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.

A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.